Exciting Co-formulation Advancements by Ascletis Pharma
Ascletis Pharma Inc. has made a significant stride in obesity treatment with the co-formulation of ASC36, a monthly amylin receptor agonist, and ASC35, a GLP-1R/GIPR dual agonist. These innovative therapies aim to offer better patient outcomes through advanced pharmacokinetic profiles and a robust efficacy in weight reduction.
Collaboration of Technologies for Optimized Therapeutics
Using proprietary technology, Ascletis successfully merged two leading candidates: ASC36 and ASC35. Both agents are designed to be administered subcutaneously once a month, harnessing the company's Ultra-Long-Acting Platform (ULAP) technology. This integration not only exhibits a comparable pharmacokinetic profile to their standalone forms but also supports their potential for effective long-term management of obesity.
Results from Preclinical Studies
In rigorous preclinical studies involving non-human primates, the results were compelling. Co-administration of ASC36 and ASC35 demonstrated successful weight reduction capabilities, showing a 51% greater relative weight loss compared to existing treatments when used together in a targeted way. This positioning suggests that the combined effects of these two agents could surpass those of current popular therapies.
Further studying of ASC36 alone revealed a relative body weight reduction that was 32% more effective compared to eloralintide in diet-induced obese rats. Similarly, ASC35 exceeded expectations, presenting a remarkable 71% increase in weight loss compared to tirzepatide in mice trials.
Stability and Formulation Strength
One notable aspect of the ASC36 and ASC35 co-formulation is its stability. It demonstrated excellent chemical composition, revealing no signs of aggregation or precipitation due to fibrillation at neutral pH, a common issue in peptide formulations. This stability is crucial as unstable formulations could lead to reduced potency, making ASC36 and ASC35 a more reliable option for both patients and healthcare providers.
Insights from Company Leadership
According to Dr. Jinzi Jason Wu, Founder and CEO of Ascletis, "With compelling preclinical data, we see a robust future for the co-formulation of ASC36 and ASC35. We believe this could reshape the landscape of weight management therapeutics available today, offering a multi-faceted approach that outcompetes single-agent therapies." This outlook reflects the company's confidence in the effectiveness of their technology and research capabilities.
Upcoming Investigational New Drug Application
Plans are underway for the submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration for this co-formulation, anticipated for the second quarter of 2026. This critical step will pave the way for facilitating clinical trials and eventually offering these innovative options to the public.
Future Conference Call Details
Ascletis has scheduled a conference call in Mandarin to discuss these developments in greater detail. This call will take place at 10:00 a.m. China Standard Time on a yet-to-be-confirmed day in late 2025, showcasing Ascletis's commitment to maintaining clear communication with stakeholders.
About Ascletis Pharma Inc.
Ascletis Pharma Inc. stands at the forefront of biotechnology with a focus on developing novel treatments that address metabolic diseases, particularly obesity. With state-of-the-art AI-assisted drug discovery and ultra-long-acting drug formulations, the company continues to innovate in the field of therapeutics, expanding options for patient management.
Their pipeline reflects a commitment to bringing high-quality, effective treatments to market, underscoring an inspiring vision to improve the quality of life for individuals grappling with obesity and other metabolic disorders.
Frequently Asked Questions
What are ASC36 and ASC35?
ASC36 is a once-monthly amylin receptor agonist, while ASC35 is a GLP-1R/GIPR dual agonist. Together, they are designed for effective weight management.
How do these drugs work?
Both drugs target specific receptors in the body to improve metabolic responses, leading to significant weight loss in preclinical studies.
When is the IND submission expected?
The submission of the IND to the U.S. FDA is expected to occur in the second quarter of 2026.
What makes this co-formulation unique?
The combination of ASC36 and ASC35 shows enhanced weight loss compared to their individual use and has demonstrated superior stability and reliability.
How can I find out more about Ascletis?
More information can be gleaned by visiting their company website or attending their upcoming conference call for detailed updates on their initiatives.
